CRBU — Q2 2026 Financial Report Analysis

Q2 2026: cut spending by a third, then ran out of road

Caribou Biosciences' second quarter (April to June 2026) looked like a company getting ready for its biggest step yet: the U.S. Food and Drug Administration (FDA) had agreed the design of a pivotal phase 3 trial (the large final-stage study usually needed for approval) for its lead lymphoma therapy vispa-cel, quarterly R&D spending was down 32% from a year earlier, and management said in August that cash would last to the end of 2027. Seven weeks later, on October 6, 2026, the company reversed course. The board approved stopping both of its clinical programs, laying off most staff and looking for a buyer or merger partner, saying the "current financing environment for allogeneic CAR-T cell therapies" had made it too hard to raise the money for the phase 3 trial. Read the Q2 numbers below with that in mind: they describe a business that no longer exists in the same form.

At a glance

• $113.8 million in cash and investments at June 30, 2026 (down from $142.8 million at the end of 2025). With the drug programs stopped, this money, minus wind-down costs, is most of what Caribou now offers a buyer or its shareholders.
• $24.3 million net loss, or $0.24 per share, versus $54.1 million ($0.58) a year earlier. About $21.3 million of last year's loss was one-off write-downs, so the real improvement came mainly from the 2025 cost cuts.
• Share count up 11.4% in six months (95.1 million to 106.0 million), because Caribou sold stock on the open market at about $2.03 a share to fund itself. That raised $20.1 million but spread ownership more thinly.

What Caribou was developing

Caribou uses CRISPR gene editing to make "off-the-shelf" (allogeneic) CAR-T cell therapies: immune cells from healthy donors, engineered to attack cancer and stored ready to use. Approved CAR-T products today are autologous, meaning each one is made from the patient's own cells over several weeks, which is costly and leaves some patients too sick to wait. Caribou's pitch was similar results without the wait.

The clinical data reported in the quarter were the strongest the company had shown:

• Vispa-cel (lymphoma). In the 27 second-line large B cell lymphoma patients who got the dose and donor match planned for phase 3, 82% responded, 67% had a complete response (no detectable cancer on scans), and the median time before the disease worsened again was 17.1 months. On May 7 Caribou said it had FDA alignment on ANTLER-3, a randomized trial of about 250 patients.
• CB-011 (multiple myeloma). Of 12 patients at the chosen dose who had not had prior BCMA-targeted therapy, 92% responded, 83% reached complete response or better, and half were still in complete response or better at 15 months.

These were small, early-stage, single-arm results, and the company itself cautions against comparing them with trials of approved products. Still, the October decision was not driven by bad data: the company says it stopped because it could not raise the money.

The numbers

Caribou has no product sales. Its small revenue comes from licensing its gene-editing patents to other companies. Revenue fell because Q2 2025 included a $1.0 million milestone payment with nothing similar this year, and because an information-rights agreement with Pfizer, which contributed $0.6 million in Q2 2025, expired on June 29, 2026. Margins don't mean anything for a company at this stage, so the table leaves them out.

Where the spending cut came from. R&D fell $8.8 million. According to the 10-Q, $3.3 million came from lower contract research and manufacturing work for its trials, $2.6 million from lower personnel costs, $2.0 million from other R&D costs, and the rest from facilities and license fees. The company ties the personnel and other R&D declines to the April 2025 restructuring, when Caribou dropped its preclinical research and two other clinical programs and cut 47 jobs, about 32% of staff. Payments to outside contractors that run trials and make cells fell from $10.4 million to $7.1 million. In other words, by mid-2026 Caribou was spending on two phase 1 trials, not yet on a large new study.

Takeaway: The Q2 report showed a company that had brought its quarterly operating loss down to about $25 million and had a phase 3 design agreed with the FDA, but not the money to run that trial. The October 6 decision made that gap final. From here, CRBU's value depends mostly on how much of the $113.8 million is left after wind-down costs and what a strategic deal pays for the company or its technology. The quality of the trial data matters much less now.

What the headline numbers hide

• Last year's loss was inflated by one-offs, so the "loss more than halved" headline overstates the improvement. Q2 2025 included $12.2 million of impairments (write-downs of tenant improvements, a lease asset and lab equipment tied to the 2025 restructuring) and a $9.2 million write-off of its stake in Edge Animal Health. Remove those $21.3 million and the year-ago net loss was about $32.8 million, so the underlying loss fell about 26%, not 55%.
• Cash burn matched the accounting loss. Over six months Caribou used $49.8 million in operating cash against a $49.4 million net loss. Stock-based compensation ($4.8 million) is a non-cash cost, but it was cancelled out by paying down bills (accounts payable down $2.6 million, accrued expenses down $3.4 million). No working-capital timing effect flattered the result.
• Lower losses per share were partly paid for with dilution. Caribou sold 10.1 million shares through its at-the-market program (selling stock gradually into the market) in the first half, 9.0 million of them in Q2 at an average $2.03. Shares outstanding reached 107.2 million by August 7. It had $75.2 million of capacity left under that program, which tells you how the company planned to fund itself before the October decision.
• Interest income is shrinking along with the cash. Other income fell from $2.6 million to $1.1 million, mostly because interest earned on securities dropped $1.1 million. A smaller cash pile earns less, so this cushion keeps getting thinner.
• The runway statements no longer describe the plan. The 10-Q (filed August 13) said cash would fund operations for at least 12 months, and the earnings release said "to the end of 2027", including CB-011 expansion and ANTLER-3 start-up. Both statements came before the October restructuring and assumed a business plan that has since been dropped.

What changed on October 6, and what it costs

According to the October 6 8-K, Caribou expects $15 million to $19 million in restructuring costs, mostly in Q4 2026. That is about $10 million to $11 million for severance and benefits, plus $5 million to $8 million to wind down the ANTLER and CaMMouflage trials. The company says it cannot yet estimate other charges, including those tied to its facility lease, contract terminations or asset write-downs, and will file an amended 8-K when it can. Those other charges matter: at June 30 the balance sheet carried $26.7 million of operating lease liabilities, and the company says it will try to sublease or terminate its facilities. Most staff are expected to leave in Q4 2026. A small team stays to run the strategic process, and the CFO's employment ends once a definitive deal is signed. Wedbush Securities is the financial adviser, and the company has set no timeline.

For a sense of scale (our arithmetic, not a company figure): $113.8 million divided by the 107.2 million shares outstanding on August 7 is about $1.06 of cash per share at June 30, before Q3 spending, the $15 million to $19 million restructuring bill, and any lease or contract exit costs. Q3 spending won't be reported until the next 10-Q.

Outlook

There is no financial guidance to track any more. The questions now are:

1. How much cash is left at September 30 (the Q3 10-Q, due around mid-November 2026), and how much more is spent in Q4 as severance and trial wind-down costs are paid.
2. What the facility lease costs to exit. This is the largest liability the company hasn't put a number on yet.
3. What kind of deal emerges. For clinical-stage biotechs that stop their programs, the usual outcomes are a reverse merger with a private company (existing shareholders end up with a minority stake in a different business), a sale of the programs or patents, or a liquidation that returns leftover cash. Caribou has not said which it prefers, and it says it won't give updates until the board approves a course of action.

Our read: Caribou's clinical results did not fail, but the market for off-the-shelf CAR-T funding did. The company spent $49.8 million in six months to keep two phase 1 trials going, while a 250-patient phase 3 would have needed far more than it could raise by selling stock at about $2 a share without heavy dilution. For shareholders, the useful figure is no longer the quarterly loss. It is the cash that remains after the wind-down, plus whatever a buyer will pay for vispa-cel, CB-011 and the chRDNA editing patents.

Sources: Caribou's Form 10-Q for the quarter ended June 30, 2026, its Q2 2026 earnings release, and its October 6, 2026 Form 8-K on the strategic review and restructuring.